Ask sales for the Certificate of Analysis matched to the offered or supplied lot; it records the tests actually completed, applicable specifications, and reported results.

Matching batch COA available.

FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →

FDA PCAC: 7 peptides under review. Read →

HGH Fragment 176-191

Name: HGH Fragment 176-191
Brand: Vialdyne
SKU: hgh-fragment-176-191

C-terminal fragment of human growth hormone (176–191)

≥ 99.0%CAS 66004-57-7GH-Axis Peptides

Vialdyne primary owner

HGH Fragment 176-191 release-packet review for pharmacy QA and regulated procurement

This Vialdyne page is the primary SEO owner for buyers evaluating HGH Fragment 176-191 through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.

Use this page when the buyer needs release documentation, lot-specific QA evidence, and destination-market fit before supplier approval.
Ask for a release packet when the next decision is pharmacy qualification, recurring inventory planning, or internal QA-file review.
Broad catalog economics and analytical/reference-standard method packets sit outside this page's compounding-procurement focus.

Overview

HGH Fragment 176-191 is the unmodified 16-residue C-terminal segment of human growth hormone, lifted directly from positions 176 through 191 of the 191-residue native HGH protein. The fragment preserves C-terminal-region lipolytic activity while leaving behind the central-region anabolic and IGF-1-stimulating effects that are characteristic of the full-length GH molecule. The critical distinction at the procurement-file level is between this SKU, which is the unmodified native sequence, and AOD9604, whose N-terminal residue is tyrosine (the tyrosine was introduced to support iodination tracking) where this native fragment carries phenylalanine; the two molecules are chemically distinct and produce different ESI-MS signatures, despite a confusingly similar catalogue naming convention across the broader peptide market. HGH Fragment 176-191 carries a ≥99.0% main-peak HPLC catalogue target. Ask sales for the batch COA matched to the offered lot; it records the identity and purity work actually completed. The reference values are CAS 66004-57-7, formula C78H123N23O22S2, average MW 1799.1 g/mol, and sequence FLRIVQCRSVEGSCGF. If the buyer's written procedure requires reduced-versus-oxidised-form evidence, agree the ESI-MS or RP-HPLC method, reporting, timing, and cost before quotation. Six nominal strengths from 1 to 15 mg cover bench-scale and dispensing-scale workflows.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

How HGH Fragment 176-191 is sourced

Sourced for

503A / 503B compounding dispensed under physician supervision
Research into somatotropic-axis pharmacology

Buyer fit

academic and contract research laboratories
503A / 503B compounding pharmacies

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Procurement note: For sterile-filled vials, confirm whether sterility, endotoxin, and CCI are included in the agreed release packet. For loose lyophilized powder, request the batch COA and separately scope any sequence-level evidence required by the buyer's written procedure.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS: 66004-57-7
Molecular Formula: C78H123N23O22S2
Molecular Weight: 1799.1 g/mol
Sequence: FLRIVQCRSVEGSCGF
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 1 mg – 15 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 30-40 minutes
MOQ: On request
Lead time: 10–18 days
Storage: -20°C, protect from light

Certificate of Analysis

Representative COA previews for HGH Fragment 176-191; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG107 · 99.68%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG108 · 99.39%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG109 · 99.42%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG104 · 99.66%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG105 · 99.53%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG106 · 99.11%

Browse all published COAs

Independent analytical testing

Product- and strength-matched first-page previews are shown separately from Vialdyne's lot-specific Batch COAs. Reference the report number when requesting the complete, high-resolution file from sales.

Third-party testView report record →

HGH Fragment 176-191

5 mg · HPLC / MS

FRAG5-20260814S6492

Third-party testing in Tianjin

Independent HPLC and mass-spectrometry reports from Qorix , the professional, authoritative third-party analytical laboratory at tjqxgd.com, affiliated with the Tianjin International Joint Academy of Biomedicine.

Regulatory note

Because the unmodified fragment and the AOD9604-modified analog (bearing an N-terminal tyrosine) are not chemically equivalent, they are readily mixed up. Before you place an order, verify the precise fragment identity — unmodified versus AOD9604-modified — against the batch COA.

Selected literature

Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-E526.
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507.
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.
Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15.
More MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77.

Frequently asked questions

How do I distinguish HGH Fragment 176-191 from AOD9604 at the analytical level?▾

Mass spec at receiving inspection is the diagnostic test. The two molecules differ at the N-terminal residue, AOD9604 carries an N-terminal tyrosine where this native fragment carries phenylalanine, producing a 16-residue molecule with theoretical MW around 1815 Da, while HGH Fragment 176-191 is the unmodified 16-residue sequence at 1799.1 Da theoretical. The ~16 Da delta (tyrosine adds one oxygen relative to phenylalanine) is unambiguous on an ESI-MS scan and can be included when required by the buyer’s written analytical scope. Secondary confirmation comes from RP-HPLC retention time, the tyrosine hydroxyl shifts AOD9604 elution relative to the native fragment under typical gradient conditions. Either way, never rely on label alone; the released-batch mass must match the ordered form.

What does the intramolecular disulfide bond in HGH Fragment 176-191 mean for handling?▾

The fragment sequence FLRIVQCRSVEGSCGF contains two cysteines at internal positions 7 and 14. Under reducing conditions during synthesis the cysteines remain as free thiols; under oxidative conditions during downstream storage and reconstitution they can pair into an intramolecular disulfide bridge. The reduced and oxidised species differ by 2 Da in ESI-MS and elute at distinct RP-HPLC retention times, making the form readily distinguishable at QC. Most published research uses the oxidised (disulfide-bridged) form, which is the more stable solid-state species. The released-batch COA documents which form the lot represents, which matters operationally for any protocol that specifies one form or the other.

Related peptides

Buyers who view HGH Fragment 176-191 also ask about:

AOD9604

≥99.0%

Modified HGH fragment 176–191 (anti-obesity drug candidate)

CAS: 221231-10-3
Vial: 2 mg–10 mg

MOQ on requestGet quote →

29-mer

Sermorelin

≥99.0%

GHRH 1-29 fragment

CAS: 86168-78-7
Vial: 2 mg–10 mg

MOQ on requestGet quote →

See full catalog

HGH Fragment 176-191

C-terminal fragment of human growth hormone (176–191)

≥ 99.0%CAS 66004-57-7GH-Axis Peptides

Vialdyne primary owner

HGH Fragment 176-191 release-packet review for pharmacy QA and regulated procurement

Use this page when the buyer needs release documentation, lot-specific QA evidence, and destination-market fit before supplier approval.
Ask for a release packet when the next decision is pharmacy qualification, recurring inventory planning, or internal QA-file review.
Broad catalog economics and analytical/reference-standard method packets sit outside this page's compounding-procurement focus.

Overview

Applications & buyer fit

How HGH Fragment 176-191 is sourced

Sourced for

503A / 503B compounding dispensed under physician supervision
Research into somatotropic-axis pharmacology

Buyer fit

academic and contract research laboratories
503A / 503B compounding pharmacies

Documentation that ships

Certificate of Analysis (COA)
HPLC Chromatogram
Mass-spec identity (ESI-MS)
Counter-ion (acetate vs TFA)
Sterile-fill release pack (sterility, CCI, fill-weight)
Bacterial endotoxin (LAL, USP <85>)
Stability data on request
SDS / MSDS

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS: 66004-57-7
Molecular Formula: C78H123N23O22S2
Molecular Weight: 1799.1 g/mol
Sequence: FLRIVQCRSVEGSCGF
Appearance: White to off-white lyophilized powder
Purity (HPLC): ≥ 99.0%
Strength: 1 mg – 15 mg
Packaging: 10 vials/box · base pack (multiples of 10)
Half-life: ≈ 30-40 minutes
MOQ: On request
Lead time: 10–18 days
Storage: -20°C, protect from light

Certificate of Analysis

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG107 · 99.68%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG108 · 99.39%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG109 · 99.42%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG104 · 99.66%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG105 · 99.53%

VerifiedRequest full COA →

HGH Fragment 176-191

VD260428-FRAG106 · 99.11%

Browse all published COAs

Independent analytical testing

Third-party testView report record →

HGH Fragment 176-191

5 mg · HPLC / MS

FRAG5-20260814S6492

Third-party testing in Tianjin

Regulatory note

Selected literature

Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-E526.
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507.
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449.
Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15.
More MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77.

Frequently asked questions

How do I distinguish HGH Fragment 176-191 from AOD9604 at the analytical level?▾

What does the intramolecular disulfide bond in HGH Fragment 176-191 mean for handling?▾

Related peptides

Buyers who view HGH Fragment 176-191 also ask about:

AOD9604

≥99.0%

Modified HGH fragment 176–191 (anti-obesity drug candidate)

CAS: 221231-10-3
Vial: 2 mg–10 mg

MOQ on requestGet quote →

29-mer

Sermorelin

≥99.0%

GHRH 1-29 fragment

CAS: 86168-78-7
Vial: 2 mg–10 mg

MOQ on requestGet quote →

See full catalog